Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2021-06-20
2022-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Home-based Exercise
Participants receive usual care without any additional structured exercise program. Assessments are performed at baseline and after 12 weeks.
Home-based Exercise Program
Participants follow a 12-week home-based exercise program including aerobic, strengthening, and flexibility exercises. Assessments are done at baseline and after 12 weeks.
Control
Participants receive usual care without any additional structured exercise program. Assessments are performed at baseline and after 12 weeks.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Home-based Exercise Program
Participants follow a 12-week home-based exercise program including aerobic, strengthening, and flexibility exercises. Assessments are done at baseline and after 12 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Voluntary participation in the study
* Diagnosis of fibromyalgia according to the 2016 ACR criteria
* Female gender
* Pain severity score of ≥4/10 on the Visual Analog Scale (VAS)
Exclusion Criteria
* History of malignancy
* Pre-existing neurological, endocrine, infectious, or inflammatory rheumatic diseases
* Severe psychiatric disorders
* Advanced cardiac, respiratory, or musculoskeletal conditions that would prevent exercise
* Participation in an exercise or physical therapy program within the last 6 months
* Any changes to current medical treatment during the study period
18 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kutahya Health Sciences University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nazlı Karaman, MD
Role: PRINCIPAL_INVESTIGATOR
Kütahya Health Sciences University, Department of Physical Medicine and Rehabilitation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kütahya Health Sciences University Hospital
Kütahya, Kütahya, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan: Home-Based Exercise Study Protocol
Document Type: Study Protocol and Statistical Analysis Plan: Full Study Protocol
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Individual participant data and supporting information will not be shared.
View DocumentOther Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMS-HBEP-2025
Identifier Type: OTHER
Identifier Source: secondary_id
EC-2021-02/10
Identifier Type: -
Identifier Source: org_study_id